AUG 2 2000

K001590

UROGYN

SECTION 10.
SUMMARY

Urogyn Ltd.
Diamond Tower (26th Floor)
3A Jabotinski Street
Ramat Gan 52520, Israel
Telephone: 972-3-6122254
Fax: 972-3-6133275

Contact Person (and U.S. Agent)
Kenneth T. Burck
34 Fairway Circle
Natick, MA 01760
Telephone & Fax 1-508-653-5891

Date: 21 July 2000

Name of Device: Manual Gynecological Needle Driver - DND 101™.

Classification Name: Gastro-Urological Manual Surgical Device

Intended Use: Sacrospinous ligament fixation procedure.

Indications for Use: The DND 101™ Needle Driver is indicated for the treatment of female vaginal prolapse.

Technical, Non Clinical & Clinical differences from the Deschamps™ (or Mia Hook) predicate device:
The DND 101™ is a flexible, non-rigid device. Its needle is positioned on the surgeon's finger allowing an accurate palpation and optimal location of the suture material, as opposed to the Deschamps ™ (or Mia Hook) device for which direct palpation is complicated. The DND 101™ allows control of tissue penetration and optimal safety to the patient and surgeon.

Conclusions: From Urogyn's experience and from the experience of an unbiased expert in the field of Urology (see appendix 3), we believe that the Urogyn design offers a safer, equally effective alternative to the Deschamps™ (or Mia Hook) device for the treatment of female vaginal prolapse.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

AUG 2 2000

Urogyn Ltd.
c/o Kenneth T. Burck
34 Fairway Circle
Natick, MA 01760

Re: K001590
DND 101 Digital Needle Driver
Dated: March 28, 2000
Received: May 17, 2000
Regulatory Class: II
21CFR 884.4530/Procode: 85 KNA

Dear Mr. Burck:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4591. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Daniel G. Schultz, M.D.
Captain, USPHS
Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure(s)

[redacted]

UROGYN

510K Number: K001590

Device Name: DND 101™ Needle Driver

Indications for Use:
This device is indicated for use in the treatment of female vaginal prolapse.

(PLEASE DO NOT WRITE BELOW THIS LINE. CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

David A. Lepore

(Division Sign-Off)
Division of Reproductive, Abdominal, ENT,
and Radiological Devices
510(k) Number K001590

Prescription Use ✓ -or- Over-The-Counter Use _____
(Optional Format 3-10-98)